切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (03) : 210 -214. doi: 10.3877/cma.j.issn.1674-1358.2022.03.011

病例报告

抗干扰素γ自身抗体综合征导致哥伦比亚分枝杆菌播散性感染一例
谭洁1, 詹森林1, 邓国防1, 张培泽1,()   
  1. 1. 518000 深圳市,深圳市第三人民医院肺病二科
  • 收稿日期:2021-09-07 出版日期:2022-06-15
  • 通信作者: 张培泽
  • 基金资助:
    "登峰计划"高水平医院建设开放课题(No. FSSYKF-2020001)

A case of Mycobacterium Columbia disseminated infection caused by anti-interferon γ autoantibody syndrome

Jie Tan1, Senlin Zhan1, Guofang Deng1, Peize Zhang1,()   

  1. 1. Department of Pulmonary Medicine and Tuberculosis, the Third People’s Hospital of Shenzhen, Shenzhen 518000, China
  • Received:2021-09-07 Published:2022-06-15
  • Corresponding author: Peize Zhang
引用本文:

谭洁, 詹森林, 邓国防, 张培泽. 抗干扰素γ自身抗体综合征导致哥伦比亚分枝杆菌播散性感染一例[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(03): 210-214.

Jie Tan, Senlin Zhan, Guofang Deng, Peize Zhang. A case of Mycobacterium Columbia disseminated infection caused by anti-interferon γ autoantibody syndrome[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(03): 210-214.

目的

探讨抗干扰素(IFN)γ抗体综合征导致非结核分枝杆菌(哥伦比亚分枝杆菌)播散性感染的临床特点和治疗方法。

方法

1例66岁的老年女性因"反复发热伴淋巴结肿痛6个月"于2020年11月21日至深圳市第三人民医院住院治疗。分析该例IFN-γ抗体综合征导致的哥伦比亚分枝杆菌播散性感染者的临床诊疗经过,并行相关文献复习。

结果

该患者于外院行淋巴结活检组织、肺泡灌洗液宏基因组二代测序(mNGS)检测均提示哥伦比亚分枝杆菌感染。正电子发射计算机断层显像(PET-CT)示多处淋巴结肿大伴代谢升高,全身多处骨质破坏,右肺上叶前段病变伴高代谢。查体:全身皮疹,多处浅表淋巴结肿大,部分溃破伴少量脓液。入院查患者外周血:免疫球蛋白G定量、免疫球蛋白A定量、T淋巴细胞绝对计数、CD4+ T和CD8+ T细胞计数均正常。患者血液标本行IFN-γ抗体检测滴度为32 700 ng/ml(正常值< 5 000 ng/ml),确诊为抗IFN-γ自身抗体免疫缺陷综合征导致的哥伦比亚分枝杆菌播散性感染。给予抗哥伦比亚分枝杆菌治疗,并给予丙种球蛋白和激素治疗,患者皮疹消退,破溃淋巴结愈合,肿大淋巴结明显缩小,病情好转,门诊继续给予抗非结核分枝杆菌治疗并随访。

结论

临床上对于非结核分枝杆菌播散性感染者,需要考虑到IFN-γ抗体综合征的可能,应行IFN-γ抗体检测,在针对病原体治疗的同时需进行免疫治疗。

Objective

To investigate the clinical characteristics and treatment of a patient with nontuberculous mycobacterium (Mycobacterium Columbia) disseminated infection caused by anti-interferon γ (IFN-γ) autoantibody syndrome.

Methods

A 66-year-old woman was hospitalized on November 21st, 2020 in Shenzhen Third People’s Hospital for "recurrent fever, with swollen and painful lymph nodes for 6 months" . The clinical course of this case with Mycobacterium Columbia disseminated infection caused by anti-IFN-γ syndrome was analyzed and relevant literatures were reviewed.

Results

Mycobacterium Columbia infection was identified both by metagenomic next-generation sequencing (mNGS) from lymph node tissue and alveolar lavage fluid of this patient performed in other hospital. Positron emission tomography computer tomography (PET-CT) showed multiple lymph node enlargement, multiple bone destruction throughout the body and consolidated right upper lobe of the lung with significant metabolic activity of this patient. Physical examination showed diffused skin rash and multiple superficial enlarged lymph nodes with ulcer and a few pus. Peripheral blood of this patient: quantification of immunoglobulin G and immunoglobulin A, absolute count of T-lymphocyte, count of CD4+ T cell and CD8+ T cell were all normal. The blood specimen was detected with IFN-γ autoantibodies titer as 32 700 ng/ml (normal value < 5 000 ng/ml), and the diagnosis of Mycobacterium Columbia disseminated infection caused by anti-IFN-γ, autoantibody immunodeficiency syndrome was confirmed. Anti-Mycobacterium Columbia treatment and gamma globulin and hormone therapy were carried out. The patient’s rash subsided, the ruptured lymph node healed, the enlarged lymph node reduced significantly, and the condition improved. Anti-nontuberculous mycobacterium treatment was continued during the outpatient treatment and follow-up.

Conclusions

Clinically, for disseminated non-tuberculous mycobacterium-infected individuals, the possibility of anti-interferon antibody syndrome should be taken into account, and anti-IFN-γ detection should be performed to achieve the purpose of diagnosis, and immunotherapy should be performed besides treatment based on pathogen.

图1 患者治疗前胸部CT注:2020年11月29日胸部CT:右上肺前段实变,支气管扩张
图2 患者治疗前典型部位特征注:A:腋窝淋巴结溃破,B:前臂皮疹,C:双下肢皮疹
图3 患者治疗后典型部位变化注:A:腋窝淋巴结愈合,B:前臂皮疹消失,C:双下肢皮疹消失
[1]
Döffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity[J]. Clin Infect Dis,2004,38(1):e10-e14.
[2]
Höflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans[J]. Blood,2004,103(2):673-675.
[3]
Kampitak T, Suwanpimolkul G, Browne S, et al. Anti-interferon-γ autoantibody and opportunistic infections: case series and review of the literature[J]. Infection,2011,39(1):65-71.
[4]
Tang BS, Chan JF, Chen M,et al. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon[J]. Clin Vaccine Immunol,2010,17(7):1132-1138.
[5]
Aoki A, Sakagami T, Yoshizawa K, et al. Clinical significance of interferon-γ neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease[J]. Clin Infect Dis,2018,66(8): 1239-1245.
[6]
Guo J, Ning XQ, Ding JY, et al. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections[J]. J Exp Med,2020,217(12):e20190502.
[7]
Hong GH, Ortega-Villa AM, Hunsberger S, et al. Natural history and evolution of anti-interferon-γ autoantibody-associated immunodeficiency syndrome in Thailand and the United States[J].Clin Infect Dis,2020,71(1):53-62.
[8]
Chen YP, Yen YS, Chen TY, et al. Systemic Mycobacterium kansasii infection mimicking peripheral T-cell lymphoma[J]. Apmis,2008,116(9):850-858.
[9]
侯志飞,赵学森. 干扰素诱导跨膜蛋白抗病毒机制的研究进展[J/CD]. 中华实验和临床感染病杂志(电子版),2018,12(3):212-215.
[10]
Chan JF, Trendell-Smith NJ, Chan JC, et al. Reactive and infective dermatoses associated with adult-onset immunodeficiency due to anti-interferon-gamma autoantibody: Sweet’s syndrome and beyond[J]. Dermatology,2013,226(2):157-166.
[11]
赖冠廷,梁小娜,宾雁飞, 等. 抗γ-干扰素自身抗体阳性患者5例临床特征分析并文献复习[J]. 中国实用内科杂志,2020,40(10):840-849.
[12]
Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases[J]. Biomol Concepts,2018,9(1):64-79.
[13]
佟晔,张昕宇,周志安, 等. 以非伤寒沙门菌菌血症首诊的非霍奇金淋巴瘤一例[J/CD]. 中华实验和临床感染病杂志(电子版),2020,14(2):167-171.
[14]
Krisnawati DI, Liu YC, Lee YJ, et al. Blockade effects of anti-interferon- (IFN-) γ autoantibodies on IFN-γ-regulated antimicrobial immunity[J]. J Immunol Res,2019,2019:1629258.
[15]
Wu UI, Wang JT, Sheng WH, et al. Incorrect diagnoses in patients with neutralizing anti-interferon-gamma-autoantibodies[J]. Clin Microbiol Infect,2020,26(12):1684.
[16]
Murcia MI, Tortoli E, Menendez MC, et al. Mycobacterium colombiense sp. nov., a novel member of the Mycobacterium avium complex and description of MAC-X as a new ITS genetic variant[J]. Int J Syst Evol Microbiol,2006,56(Pt 9):2049-2054.
[17]
Maurer FP, Pohle P, Kernbach M, et al. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex[J]. Clin Microbiol Infect,2019,25(3):379.
[18]
Rujirachun P, Sangwongwanich J, Chayakulkeeree M. Triple infection with Cryptococcus, varicella-zoster virus, and Mycobacterium abscessus in a patient with anti-interferon-gamma autoantibodies: a case report[J]. BMC Infect Dis,2020,20(1):232.
[19]
Czaja CA, Merkel PA, Chan ED, et al. Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-gamma autoantibody[J]. Clin Infect Dis,2014,58(6):e115-118.
[20]
Browne SK, Zaman R, Sampaio EP, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection[J]. Blood,2012,119(17):3933-3939.
[21]
Ochoa S, Ding L, Kreuzburg S, et al. Daratumumab (anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-IFN-γ autoantibodies[J]. Clin Infect Dis,2021,72(12):2206-2208.
[22]
Rocco JM, Rosen LB, Hong GH, et al. Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies[J]. J Transl Autoimmun,2021,4:100102.
[23]
Harada M, Furuhashi K, Karayama M, et al. Subcutaneous injection of interferon gamma therapy could be useful for anti-IFN-gamma autoantibody associated disseminated nontuberculous mycobacterial infection[J]. J Infect Chemother,2021,27(2):373-378.
[24]
Chetchotisakd P, Anunnatsiri S, Nanagara R, et al. Intravenous cyclophosphamide therapy for anti-IFN-gamma autoantibody-associated Mycobacterium abscessus infection[J]. J Immunol Res,2018,2018:6473629.
[25]
Jutivorakool K, Sittiwattanawong P, Kantikosum K, et al. Skin manifestations in patients with adult-onset immunodeficiency due to anti-interferon-gamma autoantibody: A relationship with systemic infections[J]. Acta Derm Venereol,2018,98(8):742-747.
[1] 李晨曦, 谭小容, 魏巍, 李慕秋, 龚忠诚. 三级淋巴结构在口腔癌中的特征及意义[J]. 中华口腔医学研究杂志(电子版), 2023, 17(05): 315-321.
[2] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[3] 闫甲, 刘双池, 王政宇. 胆囊癌肿瘤标志物的研究和应用进展[J]. 中华普通外科学文献(电子版), 2023, 17(05): 391-394.
[4] 薛永婷, 高峰, 王雅楠, 屈莲平. 溶瘤病毒治疗在结直肠癌中的应用[J]. 中华普通外科学文献(电子版), 2023, 17(05): 380-384.
[5] 陈坤, 何傅梅, 方婷, 陈文瑞. 血清sCD73与EGFR/ALK野生型非小细胞肺癌免疫治疗效果的相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 504-507.
[6] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[7] 阎凯, 付雍, 章正涛, 卢文峰, 王毅州, 巫国谊, 张海斌. 中晚期肝癌疗效预测模型暨肝癌类器官模型研究进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 348-351.
[8] 蔡晨, 龚伟. 免疫治疗在胆道肿瘤中的应用现状及展望[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 162-166.
[9] 王健东, 全志伟. 重视胆道恶性肿瘤化疗联合靶向免疫的综合治疗[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 125-130.
[10] 陈润芝, 杨东梅, 徐慧婷. 信迪利单抗联合索凡替尼后线治疗MSS型BRAF突变的转移性结肠癌:个案报道并文献复习[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 431-435.
[11] 方洪生, 顾睿祈, 蔡国响. 结直肠癌腹膜转移免疫治疗的研究现状与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(02): 107-111.
[12] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[13] 杨镠, 秦岚群, 耿茜, 李栋庆, 戚春建, 蒋华. 可溶性免疫检查点对胃癌患者免疫治疗疗效和预后的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 305-311.
[14] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
[15] 张琪悦, 王晓东. IL-8与肿瘤免疫的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 605-613.
阅读次数
全文


摘要